Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)

BACKGROUND: The appropriate number of chemotherapy cycles for limited stage diffuse large B-cell lymphoma (DLBCL) patients without gross residual lesions after complete resection, has not been specifically questioned. We performed a multicenter, single-arm, phase 2 study to investigate the feasibili...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Yoon, Dok Hyun, Sohn, Byeong Seok, Oh, Sung Yong, Lee, Won-Sik, Lee, Sang Min, Yang, Deok-Hwan, Huh, Jooryung, Suh, Cheolwon
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5355104/
https://ncbi.nlm.nih.gov/pubmed/28076329
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14531
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak